Abivax ADR [ABVX] stock is trading at $6.40, up 1.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABVX shares have gain 14.49% over the last week, with a monthly amount drifted -6.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abivax ADR [NASDAQ: ABVX] stock has seen the most recent analyst activity on March 20, 2025, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $12. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on December 04, 2024, and set its price target to $33. On July 29, 2024, Laidlaw initiated with a Buy rating and assigned a price target of $48 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $43 on May 20, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $42 as its price target on April 29, 2024. Guggenheim started tracking with a Buy rating for this stock on April 29, 2024, and assigned it a price target of $50. In a note dated November 14, 2023, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $15 on this stock.
Abivax ADR [ABVX] stock has fluctuated between $4.77 and $16.63 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Abivax ADR [NASDAQ: ABVX] shares were valued at $6.40 at the most recent close of the market. An investor can expect a potential return of 87.5% based on the average ABVX price forecast.
Analyzing the ABVX fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -18.84%, Pretax Profit Margin comes in at -19.94%, and Net Profit Margin reading is -19.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -1.1 and Total Capital is -0.83. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.04 points at the first support level, and at 5.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.69, and for the 2nd resistance point, it is at 6.99.
Ratios To Look Out For
For context, Abivax ADR’s Current Ratio is 1.82. As well, the Quick Ratio is 1.82, while the Cash Ratio is 2.78.
